CLINICAL TRIAL: MULTICENTER TRIAL OF CTLA4IG (ABATACEPT) PLUS CYCLOPHOSPHAMIDE V

$1,899M01FY2010RRNIH

University Of California, San Diego, La Jolla CA

Investigators

Linked publications & trials

Paper 38778481 Paper 38225212 Paper 37046763 Paper 36288905 Paper 35895672 Paper 35668631 Paper 35306227 Paper 35197258 Paper 34928415 Paper 34654027 Paper 34166655 Paper 33388403 Paper 33156902 Paper 33002231 Paper 32954444 Paper 32299324 Paper 32184195 Paper 31818851 Paper 31505070 Paper 31404238 Paper 31161437 Paper 31156069 Paper 30508411 Paper 30487263 Paper 30445386 Paper 30421439 Paper 30354704 Paper 30348535 Paper 30132040 Paper 29605094 Paper 29370333 Paper 29276107 Paper 29271110 Paper 29051146 Paper 28830083 Paper 28754692 Paper 28572159 Paper 28187771 Paper 27600072 Paper 27495299 Paper 27473350 Paper 27448468 Paper 27293521 Paper 27166718 Paper 27142425 Paper 27139783 Paper 27018723 Paper 26798961 Paper 26747734 Paper 26689571 Paper 26666201 Paper 26442836 Paper 26430087 Paper 26378004 Paper 26305897 Paper 26265126 Paper 26091977 Paper 26085555 Paper 26083739 Paper 26081623 Paper 26056337 Paper 25965871 Paper 25903538 Paper 25861135 Paper 25835440 Paper 25817226 Paper 25714579 Paper 25564368 Paper 25481571 Paper 25451450 Paper 25433211 Paper 25313914 Paper 25303490 Paper 25182189 Paper 25102180 Paper 25070961 Paper 24938585 Paper 24888477 Paper 24834916 Paper 24780043 Paper 24755714 Paper 24751112 Paper 24700865 Paper 24657294 Paper 24642382 Paper 24636844 Paper 24615880 Paper 24610327 Paper 24570214 Paper 24436138 Paper 24354476 Paper 24344872 Paper 24269133 Paper 24249120 Paper 24220913 Paper 24206458 Paper 24119938 Paper 24053522 Paper 24033699 Paper 24029427

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Determine whether induction therapy with abatacept plus cyclophosphamide improves the response rate in patients with lupus nephritis compared with therapy with cyclophosphamide alone.

View original record on NIH RePORTER →